CN102948483B - Blood fat reducing milk powder and preparation method thereof - Google Patents
Blood fat reducing milk powder and preparation method thereof Download PDFInfo
- Publication number
- CN102948483B CN102948483B CN201210508501.1A CN201210508501A CN102948483B CN 102948483 B CN102948483 B CN 102948483B CN 201210508501 A CN201210508501 A CN 201210508501A CN 102948483 B CN102948483 B CN 102948483B
- Authority
- CN
- China
- Prior art keywords
- milk powder
- blood lipid
- reducing blood
- content
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 132
- 235000013336 milk Nutrition 0.000 title claims abstract description 107
- 239000008267 milk Substances 0.000 title claims abstract description 107
- 210000004080 milk Anatomy 0.000 title claims abstract description 107
- 210000004369 blood Anatomy 0.000 title claims abstract description 91
- 239000008280 blood Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 43
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 40
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 40
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 40
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 150000002632 lipids Chemical class 0.000 claims description 56
- 150000002148 esters Chemical class 0.000 claims description 40
- 235000020185 raw untreated milk Nutrition 0.000 claims description 16
- 239000011573 trace mineral Substances 0.000 claims description 15
- 235000013619 trace mineral Nutrition 0.000 claims description 15
- 235000021323 fish oil Nutrition 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 239000005862 Whey Substances 0.000 claims description 12
- 102000007544 Whey Proteins Human genes 0.000 claims description 12
- 108010046377 Whey Proteins Proteins 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 235000020183 skimmed milk Nutrition 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 108010059881 Lactase Proteins 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 5
- 235000021552 granulated sugar Nutrition 0.000 claims description 5
- 229940116108 lactase Drugs 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- OBODKGDXEIUEIH-DAWLFQHYSA-N all-trans-3-hydroxyretinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(O)CC1(C)C OBODKGDXEIUEIH-DAWLFQHYSA-N 0.000 claims 3
- 235000019197 fats Nutrition 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 25
- 238000000265 homogenisation Methods 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 8
- 229940075999 phytosterol ester Drugs 0.000 abstract description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 4
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 4
- 238000002156 mixing Methods 0.000 abstract 2
- 238000000889 atomisation Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 50
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 30
- 230000001954 sterilising effect Effects 0.000 description 20
- 235000012000 cholesterol Nutrition 0.000 description 17
- 238000005507 spraying Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 238000012856 packing Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 108010004103 Chylomicrons Proteins 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229940107071 plant stanol ester Drugs 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a blood fat reducing milk powder and a preparation method thereof. Taking the total weight of the blood fat reducing milk powder as the reference, the blood fat reducing milk powder comprises 2.2%-5.4% of phytosterol ester, 0.021%-0.068% of docosahexaenoic acid and 0.011%-0.054% of eicosapentaenoic acid. The preparation method of the blood fat reducing milk powder comprises the following steps of dosing, filtering, homogenization, concentration, atomization, dry-blending and packaging, wherein the phytosterol ester is mixed with other raw materials in the dosing step, and the dosing step is carried at the temperature of 40-50 DEG C; the homogenization step is carried out at the temperature of 37-60 DEG C; and the docosahexaenoic acid and eicosapentaenoic acid are mixed with other raw materials in the dry-blending step. The milk powder mainly comprises phytosterol ester, DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) as active compositions, and the three active compositions are enabled to play synergic effect in the milk powder, so that the effect of reducing blood fat is played.
Description
Technical field
The present invention relates to a kind of reducing blood lipid milk powder and preparation method thereof, belong to dairy products field.
Background technology
Along with improving constantly of people's living standard, people's life style also changes occurring, and crowd's spectrum of disease changes, to the morbidity of hypertension, Chronic Non-Communicable Diseases that high fat of blood is relevant with dead increasing.The feature of China's modern way of life is exactly fast pace, harmonic motion, abundant in content and form is single, therefore because bad life style causes a series of bad disease, serious threat health of people, in addition due to many-sided factors such as the intense and stimulative increase of mental emotion, dietetic nutrition unreasonable structure, the pollution of environment, the people of Smoking And Drinking increase, cause the causality disease incidences such as cardiovascular disease, cerebrovascular disease, diabetes, malignant tumour to increase, the major reason that become premature death, disables.And in the risk factors of various chronic diseases, high fat of blood is one of key factor wherein.High fat of blood can cause hypertension, bring out gall stone, and pancreatitis increases the weight of hepatitis, causes male sexual disfunction, the disease such as senile dementia, and current research prompting high fat of blood may be relevant with the morbidity of cancer.
At present, the patient of hyperlipemia is very general, and according to " Chinese residents nutrition and investigation of health conditions " result demonstration of State Council's issue in 2004, China dyslipidemia crowd has reached 1.6 hundred million.It also produces the impact can not be ignored on kidney, peripheral circulation, pancreas, pruritus, immune system, disease in the blood system.Therefore, for prevention and control high fat of blood, be more and more subject to people's attention.
The strict difinition of high fat of blood should be blood fat disorder or dyslipidemia, the concentration level that refers to blood in human body in fat eliminating matter has exceeded normal range (NR), comprises that serum total cholesterol (Tc) level raises, serum levels of triglyceride (TG) level raises, serum High Density Lipoprotein Cholesterol (HDL-C) level lowers.Divide two kinds of primary and Secondary cases.Hyperlipemia is a chronic process, conventionally without any symptom, but there do not have symptom to be not equal to blood fat to be not high, slight high fat of blood is conventionally without any uncomfortable sensation, be not easy to cause people's attention, most people is found when health check-up, but its harm to human body health can not be ignored.
The harm of hyperlipidemia be concealment, gradually, carrying out property and general, when Hyperlipemia, can make cholesterol and so on electrodeposition substance in vascular wall, form gradually atherosclerotic plaque.Research datas show in a large number, and hyperlipidemia is the important risk factor of the diseases such as headstroke, coronary heart disease, myocardial infarction.The Scandinavia Simvastatin existence test routine coronary heart disease of person 4444 and moderate hyperlipidemia patient, accept Simvastatin Treatment and observe 5 or 4 years. and coronary heart disease case fatality rate and total case fatality rate decline respectively 42% and 30%.When Blood Cholesterol increases, easily form arteriosclerosis plaque, these plaque deposits cause cerebral infarction when the cerebrovascular, and cerebral infarction is multiple is born in people above middle age, and majority has hypertension, diabetes, heart disease or hyperlipemia.Many studies have shown that, adjusts fat treatment can obviously lower incidence and the disability rate of headstroke for a long time, and meanwhile, hyperlipidemia is also to cause atherosclerotic, coronary heart disease, cerebrovas-cularaccident, finally causes the principal element of glycosuria death.In recent years, along with the change of people's dietary structure and life style, the incidence of disease of hyperlipemia rises year by year, and it has become the main factor of bringing out fatty liver.In recent years, global epidemiology investigation shows, the illness rate of fatty liver is 17%-33%.Therefore, clinician more and more payes attention to the treatment of high fat of blood.
Phytosterol (phytosterol or plant sterol) is a kind of active component being extensively present in plant, at seed, vegetable oil, fruit, vegetables equal size, will be many, what occurring in nature was the most common, content is maximum be cupreol (β-sitosterol), campesterol (campesterol), stigmasterol (stigmasterol), β-sitostamol (β-sitostanol), campestanol (campestanol) etc.Phytosterol (take stigmasterol as example) has the chemical constitution as closely similar in cholesterol (cholesterine) with animality sterol (as shown in following structural formula):
Due to the similar cholesterol of phytosterol chemical constitution, therefore, in human body digestion process, phytosterol can replace cholesterol in human body intestinal canal chylomicron Zhong position, reduces the absorption of cholesterol in human body intestinal canal, increases the excretion of cholesterol.Research shows, human body can not synthesizing phytosterol, can only from food, absorb.But the absorptivity of phytosterol is very low in meals, average out to 5% left and right.Phytosterol is not the essential composition as human body, and the food ration of human body can be different and different with people's eating habit.It is reported, Japanese intake is per capita that 300mg/d-450mg/d ，Er Northern European countries is lower, is 200mg/d-300mg/d.Weststrate (a kind of new type functional food-phytosterin ester, Chinese oil, the 26th the 3rd phase of volume of calendar year 2001) etc. the various cholesterol effects in blood of falling that are rich in phytosterol margarine have been reported, confirm to absorb every day the tablespread that is added with 8%-10% phytosterol (spreads) of average normal amount (two Europeans are approximately 209), can make serum total cholesterol and LDL-C decline 8%-13%, this is equivalent to absorb the phytosterol between 1.6g-2.0g every day.Phytosterol also has effect for reducing fat to normal adult, Sierksma (character of phytosterol, function and application, foreign medical science hygiene fascicle, the 28th the 5th phase of volume of calendar year 2001) in the double blind control research that Deng Dui76Ming health adult (44 years old mean age) carries out, find, compare with control group, take sojasterol 0.8s/a and can significantly reduce TC and LDL in blood after 3 weeks, but can not cause in blood that other liposoluble vitamin is as the decline of Hu trailing plants b element level.
Yet, although phytosterol and phytostanol have good reduction serum cholesterol effect, but its solubility in fat and water is limited, so free phytosterol and phytostanol are not the optimal selection for diet batching as cholesterol-lowering agent.Experiment shows, phytosterin ester has than the lowering cholesterol effect of the more excellent liposoluble of phytosterol and Geng Jia.Phytosterin ester is the class natural constituents in vegetable oil, and its lowering cholesterol effect is just known very early, and phytosterin ester is a kind of fatty acid ester blends that phytosterol and aliphatic acid form by chemical reaction.Phytosterin ester can change into phytosterol and aliphatic acid in human body, so its physiological function comprises the physiological function that phytosterol and aliphatic acid two parts have.It is as follows that phytosterin ester reduces cholesterol mechanism of action:
(1) because phytosterol has stronger hydrophobicity than cholesterol, so phytosterol can replace cholesterol and enters in mixed micelle (mixed micelles).This metalepsis declines the cholesterol level in protomere, thereby reduces the absorption of cholesterol.The reduction of cholesterol absorption rate likely stimulates its synthetic increasing, in a research, compare with control group meals, phytosterin ester and plant stanol ester can make respectively the synthetic increase by 53% and 38% of cholesterol, but synthetic increase can not full remuneration phytosterin ester and the degree that reduces of the caused cholesterol absorption of plant stanol ester, and therefore the total cholesterol level in circulation reduces.
(2) phytosterin ester can slow down the esterification rate of cholesterol in enterocyte.Because the sterol after esterification is easy to enter in chylomicron, nonesterified sterol is chylomicron more difficult to get access, so phytosterin ester can reduce the total amount of cholesterol in chylomicron.
Essential fatty acid (essential fatty acids, EFA) refers to that human body maintains that body eubolism is indispensable and self can not synthesize or aggregate velocity cannot meet body requirement slowly, the aliphatic acid that must provide by food.Essential fatty acid mainly comprises two kinds: the alpha-linolenic acid (18: 3) of a kind of ω of being-3 series, a kind of is the linoleic acid (18: 2) of ω-6 series, alpha-linolenic acid in human body (18: 3) can synthesize eicosapentaenoic acid (EPA) and DHA (DHA), research shows, eicosapentaenoic acid (EPA) and DHA (DHA) have different physiological roles, the edible EPA that is rich in, the fish oil of DHA, not only can effectively reduce the content of blood in human body in clearing gallbladder sterol and low-density lipoprotein, reduce the generation of angiocardiopathy, and there is anticoagulation, anti-inflammatory and the effect such as anticancer.The physiological function of DHA, EPA is as shown in table 1 below.
Table 1
Note: √ is the effective a of zoopery and has been used for the treatment of artery sclerosis b approval and is used for the treatment of hyperlipemia
Progressively raising along with people's living standard, people's dietary structure has also occurred to change significantly, the requirement of food has been turned to " high nutrition; have health to be worth " by " only can wrap up in abdomen ", people more and more focus on taking in the nutrition arrangement of meals, and milk powder has the pith that abundant nutrition has become people health care.Therefore the milk powder of, developing a kind of not only nutrition but also tool health care becomes one of this area problem demanding prompt solution.
Summary of the invention
For solving the problems of the technologies described above, the object of the present invention is to provide a kind of reducing blood lipid milk powder and preparation method thereof, this milk powder mainly comprises phytosterin ester and DHA, EPA as active component, and three brings into play synergy in milk powder, plays the effect that reduces blood fat.Reducing blood lipid milk powder of the present invention has solved independent use phytosterin ester or the required dosage of DHA, EPA is large, financial burden weight, and take in a short time the problem of poor effect.
For reaching above-mentioned purpose, the invention provides a kind of reducing blood lipid milk powder, the gross weight of this milk powder of take is benchmark, and its raw material forms and comprises phytosterin ester 2.2%-5.4%, DHA 0.021%-0.068% and eicosapentaenoic acid 0.011%-0.054%.
According to the specific embodiment of the present invention, preferably, the gross weight of this milk powder of take is benchmark, and the raw material of described reducing blood lipid milk powder forms and comprises phytosterin ester 4.2%, DHA 0.043% and eicosapentaenoic acid 0.026%.
According to the specific embodiment of the present invention, preferably, described reducing blood lipid milk powder is prepared by following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterin ester is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.
In the milk powder of above-mentioned reduction blood fat, preferably, described phytosterin ester is refinement from corn oil, extraction, concentrated and purified, and the grease that linolenic sunflower oil carries out esterification, purifying gained is rich in utilization.The buying standard (if no special instructions, the percentage composition in following table 2 is weight percentage) as shown in table 2 below of described phytosterin ester.
Table 2
In the milk powder of above-mentioned reduction blood fat, preferably, described DHA, eicosapentaenoic acid are contained in a fish oil powder, the gross weight of described fish oil powder of take is benchmark, content >=13.8% of DHA in described fish oil powder, content >=8.0% of eicosapentaenoic acid.The buying standard (if no special instructions, the percentage composition in following table 3 is weight percentage) as shown in table 3 below of described fish oil powder.
Table 3
According to the specific embodiment of the present invention, preferably, the gross weight of this milk powder of take is benchmark, and the raw material of described reducing blood lipid milk powder forms one or more the combination also comprising in raw milk, skimmed milk power, desalted whey powder and PURE WHEY etc., its content >=70%.At this, it should be noted that, in reducing blood lipid milk powder of the present invention, the content of arbitrary raw material all refers to that the dry of this raw material accounts for the content in described milk powder.
According to the specific embodiment of the present invention, preferably, the gross weight of this milk powder of take is benchmark, and the raw material of described reducing blood lipid milk powder forms and also comprises: the combination of one or more in the Bifidobacterium that the lactase that the oligoisomaltose that the maltodextrin that the white granulated sugar that the soybean oil that content is 1-3.5%, content are 5-12.5%, content are 5-20%, content are 1-3%, content are 0.08-0.64% and content are 0.01-0.05% etc.
According to the specific embodiment of the present invention, preferably, the raw material of described reducing blood lipid milk powder forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: vitamin A 300 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin E 10mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg etc.
According to the specific embodiment of the present invention, preferably, the raw material of described reducing blood lipid milk powder forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg etc.
The present invention also provides a kind of preparation method of reducing blood lipid milk powder, and it comprises the following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterol is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.In preparation method of the present invention, described filtration, concentrated, spraying and packing can be the conventional steps that milk powder is prepared in this area.
According to the specific embodiment of the present invention, preferably, the preparation method of described reducing blood lipid milk powder comprises the following steps:
Batching: at 40-50 ℃, phytosterol is mixed (wherein with other raw materials, described other raw materials can comprise: the combination of one or more in raw milk, skimmed milk power, desalted whey powder and PURE WHEY etc., the combination of one or more in soybean oil, white granulated sugar, maltodextrin, oligoisomaltose and lactase etc., multivitamin, and various trace elements), obtain mixed liquor;
Filter: by the Impurity removal in above-mentioned mixed liquor, the mixed liquor after being filtered;
Homogeneous: under 37-60 ℃, 5-15MPa homogenization pressure, the mixed liquor after above-mentioned filtration is carried out to homogeneous, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous is carried out to the concentrated sterilizing of material, and sterilization temperature is 85-93 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, dried compound powder obtains spraying;
Be dry mixed: at room temperature, DHA and eicosapentaenoic acid are mixed with the dried compound powder of above-mentioned spraying (while containing Bifidobacterium in the raw material of described reducing blood lipid milk powder forms, also together mix with the dried compound powder of described spraying being dry mixed the same DHA of step, EPA), the milk powder after being dry mixed;
Packing: after the milk powder after above-mentioned being dry mixed is packed, obtain described reducing blood lipid milk powder.
According to the specific embodiment of the present invention, more preferably, the preparation method of described reducing blood lipid milk powder comprises the following steps:
Milk collection: raw milk was unified to pump weighs, Ru Nai storehouse after the assay was approved;
Clean breast: the raw milk in Jiang Nai storehouse, through duplex strainer, filters impurity wherein;
Preheating: the raw milk that filters impurity is preheated to 40-50 ℃, squeezes into material-compound tank, prepare batching;
Batching: at 40-50 ℃, the phytosterol having melted is in advance mixed (wherein with other raw materials, described other raw materials can comprise: the combination of one or more in raw milk, skimmed milk power, desalted whey powder and PURE WHEY etc., the combination of one or more in soybean oil, white granulated sugar, maltodextrin, oligoisomaltose and lactase etc., multivitamin, and various trace elements; At this, it should be noted that, when milk powder of the present invention does not adopt raw milk to be raw material, the step of so above-mentioned milk collection, clean breast and preheating can be omitted), obtain mixed liquor;
Filter: above-mentioned mixed liquor is passed through to wherein Impurity removal of duplex strainer, the mixed liquor after being filtered;
Homogeneous: 37-60 ℃, successively under one-level homogenization pressure 5-10MPa, double-stage homogenization pressure 10-15MPa, the mixed liquor after above-mentioned filtration is carried out to homogeneous, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous, through triple effect evaporator, is carried out to the concentrated sterilizing of material, and wherein an effect evaporating temperature is 56-69 ℃, two effect evaporating temperatures are 55-65 ℃, triple effect evaporation temperature is 40-52 ℃, and sterilization temperature is 85-93 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, EAT is 170-200 ℃, and temperature of outgoing air is 82-92 ℃, and dried compound powder obtains spraying;
Be dry mixed: at room temperature, DHA and eicosapentaenoic acid are mixed with the dried compound powder of above-mentioned spraying (while containing Bifidobacterium in the raw material of described reducing blood lipid milk powder forms, also together mix with the dried compound powder of described spraying being dry mixed the same DHA of step, EPA), the milk powder after being dry mixed;
Packing: the milk powder after above-mentioned being dry mixed, by packing after pipeline feeding, sealing, coding, vanning, packing, is obtained to described reducing blood lipid milk powder.
In the preparation method of reducing blood lipid milk powder of the present invention, under 40-50 ℃ of condition, prepare burden, be different from the step that prior art is prepared burden at normal temperatures, batch temperature of the present invention can make phytosterin ester better dissolve, do not solidify, not only contribute to bring into play the blood fat reducing function of phytosterin ester, and be beneficial to carrying out smoothly of production; In addition, after batching step, without feed liquid is carried out to cold treatment, but remain at 37-60 ℃, carry out homogeneous, the problem that can avoid phytosterin ester to solidify at normal temperatures, further better dissolves phytosterin ester, better brings into play its effect; In addition, adopt the mode being dry mixed that DHA, EPA are mixed with dried other raw materials of spraying, this is because DHA, EPA are thermal sensitivity active nutrient component, and the mode that dry method is added can reduce conventional wet method and add the nutritive loss causing.
Reducing blood lipid milk powder of the present invention is usingd phytosterin ester and DHA, EPA as active component, by special preparation technology, makes three in milk powder, bring into play synergy, plays the effect that reduces blood fat.Reducing blood lipid milk powder of the present invention has solved independent use phytosterin ester or the required dosage of DHA, EPA is large, financial burden weight, and take in a short time the problem of poor effect.
The specific embodiment
Embodiment
The present embodiment provides a kind of reduction blood fat milk powder, and it comprises that following raw material forms (unit is kg, and wherein, the dry matter content of raw milk is about 11.8wt%, and the moisture in other raw materials is negligible):
Wherein, in described fish oil powder, the content of DHA is that the content of 14.3wt%, EPA is 8.6wt%; Described B B-complex comprises (in every 100g reducing blood lipid milk powder): vitamin A 512 μ gRE, vitamin D 8.1 μ g, vitamin C 75mg, vitamin e1 3.5mg α-TE, Cobastab
61.1mg; Described composite trace element comprises (in every 100g reducing blood lipid milk powder): calcium 1050mg, iron 8.0mg, zinc 4.5mg.
The present embodiment provides a kind of preparation method of above-mentioned reduction blood fat milk powder, and it comprises the following steps:
Milk collection: raw milk was unified to pump weighs, Ru Nai storehouse after the assay was approved;
Clean breast: the raw milk in Jiang Nai storehouse, through duplex strainer, filters impurity wherein;
Preheating: the raw milk that filters impurity is preheated to 50 ℃, squeezes into material-compound tank, prepare batching;
Batching: at 50 ℃, add skimmed milk power, desalted whey powder, PURE WHEY, the phytosterin ester having melted in advance, oligoisomaltose, maltodextrin, B B-complex and composite trace element in the raw milk of preheating, obtain mixed liquor;
Filter: above-mentioned mixed liquor is passed through to duplex strainer by Impurity removal wherein, the mixed liquor after being filtered;
Homogeneous: 37 ℃, successively under one-level homogenization pressure 9MPa, double-stage homogenization pressure 12MPa, the mixed liquor after above-mentioned filtration is carried out to homogeneous, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous, through triple effect evaporator, is carried out to the concentrated sterilizing of material, and wherein an effect evaporating temperature is 63 ℃, two effect evaporating temperatures are 60 ℃, triple effect evaporation temperature is 48 ℃, and sterilization temperature is 90 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, EAT is 196 ℃, and temperature of outgoing air is 88 ℃, and dried compound powder obtains spraying;
Be dry mixed: at room temperature, fish oil powder and Bifidobacterium are mixed to the milk powder after being dry mixed with the dried compound powder of above-mentioned spraying;
Packing: the milk powder after above-mentioned being dry mixed, by packing after pipeline feeding, sealing, coding, vanning, packing, is obtained to described reducing blood lipid milk powder.
Comparative example
This comparative example provides a kind of reduction blood fat milk powder, and the raw material that its raw material forms embodiment forms identical.
This comparative example also provides the preparation method of above-mentioned reduction blood fat milk powder, and it comprises the following steps:
Milk collection: raw milk was unified to pump weighs, Ru Nai storehouse after the assay was approved;
Clean breast: the raw milk in Jiang Nai storehouse, through duplex strainer, filters impurity wherein;
Batching: (25 ℃) at normal temperatures, in the above-mentioned raw milk that filters impurity, add skimmed milk power, desalted whey powder, PURE WHEY, the phytosterin ester having melted in advance, oligoisomaltose, maltodextrin, B B-complex and composite trace element, obtain mixed liquor;
Filter: above-mentioned mixed liquor is passed through to duplex strainer by Impurity removal wherein, the mixed liquor after being filtered;
Homogeneous: (25 ℃), priority are carried out homogeneous to the mixed liquor after above-mentioned filtration under one-level homogenization pressure 9MPa, double-stage homogenization pressure 12MPa at normal temperatures, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous, through triple effect evaporator, is carried out to the concentrated sterilizing of material, and wherein an effect evaporating temperature is 63 ℃, two effect evaporating temperatures are 60 ℃, triple effect evaporation temperature is 48 ℃, and sterilization temperature is 90 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, EAT is 196 ℃, and temperature of outgoing air is 88 ℃, and dried compound powder obtains spraying;
Be dry mixed: (25 ℃) at normal temperatures, fish oil powder and Bifidobacterium are mixed to the milk powder after being dry mixed with the dried compound powder of above-mentioned spraying;
Packing: the milk powder after above-mentioned being dry mixed, by packing after pipeline feeding, sealing, coding, vanning, packing, is obtained to described reducing blood lipid milk powder.
Phytosterin ester content detection
By the reducing blood lipid milk powder censorship finished product phytosterol ester content of embodiment and comparative example gained.Testing result is: in the milk powder of embodiment, phytosterol ester content is 3788mg/100g, and in the milk powder of comparative example, phytosterol ester content is 3046mg/100g.Hence one can see that, and the preparation technology of embodiment can make phytosterin ester better dissolve, and does not solidify, and makes in product the content of phytosterin ester higher, not only contributes to bring into play the blood fat reducing function of phytosterin ester, and be beneficial to carrying out smoothly of production.
Lipid-lowering effect contrast experiment
This contrast experiment's experiment crowd meets following 3 requirements: 1, the age is the male sex of 18-65 one full year of life and women totally 120 people; 2, the crowd who meets simple dyslipidemia, as serum total cholesterol (TC) >=5.2mmol/L or serum levels of triglyceride (TG) >=1.65mmol/L; 3, non-hyperlipemic patients of being in hospital, and experimental session keeps life and eating habit on ordinary days.
This contrast experiment's experimental technique comprises the following steps:
1, according to random-blind method principle, and consider the impact of age, sex, dietary factor, experiment crowd is divided into experimental group and control group, experiment A organizes 30 people, experiment B organizes 30 people, and experiment C organizes 30 people, control group 30 people, and carry out statistical analysis according to four groups of experiment crowds' blood lipid level, require edible front four groups of experiment crowds' blood lipid level there was no significant difference.
2,, in above four groups of experiment crowds, A organizes and eats milk powder A, the 25g that only adds phytosterin ester every day; B organizes and eats milk powder B, the 25g that only adds fish oil powder (being rich in DHA and EPA) every day; C group eats milk powder C, the 25g of interpolation phytosterin ester and fish oil powder (being rich in DHA and EPA) every day; D organizes to eat and does not add milk powder D, the 25g that phytosterin ester does not add fish oil powder (being rich in DHA and EPA) yet every day.Wherein, the preparation method of milk powder A, B, C, D and raw material form with embodiment basic identical, difference is that the addition of phytosterin ester, DHA and EPA is different, and in described milk powder A, B, C, D, the content of phytosterin ester, DHA and EPA is as shown in table 4 below.
3, test after 60 days, get the experiment crowd's of experimental group A, B, C and control group D limosis vein blood, measure blood lipid level, comprise serum total cholesterol (TC), triglycerides (TG), HDL-C (HDL-C), LDL-C (LDL-C), blood fat overall target (TG/HDL-C) situation of change is analyzed as follows shown in table 5.
Table 4
| Milk powder | A | B | C | D |
| Phytosterin ester content g/25g milk powder | 1.35 | 0 | 1.05 | 0 |
| DHA content mg/25g milk powder | 0 | 12 | 9.5 | 0 |
| EPA content mg/25g milk powder | 0 | 6.8 | 5 | 0 |
Table 5
Result by table 5 can draw to draw a conclusion: check is learned in the variation of blood fat overall target (TG/HDL-C) by statistics, difference has statistical significance, proof phytosterin ester and DHA, the preparation-obtained reducing blood lipid milk powder of EPA compatibility, obtained excellent synergy at reduction lipid aspects.
Claims (15)
1. a reducing blood lipid milk powder, the gross weight of this milk powder of take is benchmark, its raw material forms and comprises phytosterin ester 2.2%-5.4%, DHA 0.021%-0.068% and eicosapentaenoic acid 0.011%-0.054%;
This milk powder is prepared by following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterin ester is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.
2. reducing blood lipid milk powder as claimed in claim 1, the gross weight of this milk powder of take is benchmark, its raw material forms and comprises phytosterin ester 4.2%, DHA 0.043% and eicosapentaenoic acid 0.026%.
3. reducing blood lipid milk powder as claimed in claim 1 or 2, wherein, described phytosterin ester is refinement from corn oil, extraction, concentrated and purified, and utilizes and be rich in the grease that linolenic sunflower oil carries out esterification, purifying gained.
4. reducing blood lipid milk powder as claimed in claim 1 or 2, wherein, described DHA, eicosapentaenoic acid are contained in a fish oil powder, the gross weight of described fish oil powder of take is benchmark, content >=13.8% of DHA in described fish oil powder, content >=8.0% of eicosapentaenoic acid.
5. reducing blood lipid milk powder as claimed in claim 1 or 2, the gross weight of this milk powder of take is benchmark, its raw material forms and also comprises: the combination of one or more in raw milk, skimmed milk power, desalted whey powder and PURE WHEY, its content >=70%.
6. reducing blood lipid milk powder as claimed in claim 1 or 2, the gross weight of this milk powder of take is benchmark, and its raw material forms and also comprises: the combination of one or more in the active Bifidobacterium that the lactase that the oligoisomaltose that the maltodextrin that the white granulated sugar that the soybean oil that content is 1-3.5%, content are 5-12.5%, content are 5-20%, content are 1-3%, content are 0.08-0.64% and content are 0.01-0.05%.
7. reducing blood lipid milk powder as claimed in claim 5, the gross weight of this milk powder of take is benchmark, and its raw material forms and also comprises: the combination of one or more in the active Bifidobacterium that the lactase that the oligoisomaltose that the maltodextrin that the white granulated sugar that the soybean oil that content is 1-3.5%, content are 5-12.5%, content are 5-20%, content are 1-3%, content are 0.08-0.64% and content are 0.01-0.05%.
8. reducing blood lipid milk powder as claimed in claim 1 or 2, its raw material forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: 3-Hydroxyretinol 00 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin e1 0mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg.
9. reducing blood lipid milk powder as claimed in claim 5, its raw material forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: 3-Hydroxyretinol 00 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin e1 0mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg.
10. reducing blood lipid milk powder as claimed in claim 6, its raw material forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: 3-Hydroxyretinol 00 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin e1 0mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg.
11. reducing blood lipid milk powder as claimed in claim 1 or 2, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
12. reducing blood lipid milk powder as claimed in claim 5, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
13. reducing blood lipid milk powder as claimed in claim 6, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
14. reducing blood lipid milk powder as claimed in claim 8, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
The preparation method of the reducing blood lipid milk powder described in 15. claim 1-14 any one, it comprises the following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterol is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210508501.1A CN102948483B (en) | 2012-12-03 | 2012-12-03 | Blood fat reducing milk powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210508501.1A CN102948483B (en) | 2012-12-03 | 2012-12-03 | Blood fat reducing milk powder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102948483A CN102948483A (en) | 2013-03-06 |
| CN102948483B true CN102948483B (en) | 2014-01-15 |
Family
ID=47758310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210508501.1A Active CN102948483B (en) | 2012-12-03 | 2012-12-03 | Blood fat reducing milk powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102948483B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3000328B1 (en) * | 2013-05-20 | 2019-04-17 | Kao Corporation | Fat composition |
| CN104413147A (en) * | 2013-09-11 | 2015-03-18 | 中粮营养健康研究院有限公司 | Grease composition for formula milk powder as well as preparation method and application of grease composition |
| CN106387091A (en) * | 2016-09-09 | 2017-02-15 | 上海应用技术大学 | Phytosterin health-care nutrient powder having efficacy of reducing blood lipid and preparation method |
| CN106578078A (en) * | 2016-12-07 | 2017-04-26 | 南京苏新智慧社区服务有限公司 | Efficient-absorption oligopeptide formula goat milk powder and preparation method thereof |
| CN107771946A (en) * | 2017-10-28 | 2018-03-09 | 卜球 | A kind of formula milk and its production method for contributing to middle-aged and old cardiovascular and cerebrovascular health |
| CN108552320A (en) * | 2018-01-18 | 2018-09-21 | 青岛博智汇力生物科技有限公司 | A kind of chitosan oligosaccharide milk powder beneficial to middle-aged and the old's cardiovascular health |
| CN113545397A (en) * | 2020-04-23 | 2021-10-26 | 黑龙江唯贝美乳业有限公司 | Preparation process and processing method of milk powder of blood fat reducing milk powder |
| CN111937966A (en) * | 2020-08-27 | 2020-11-17 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of reducing blood fat and preparation method thereof |
| CN115486482A (en) * | 2021-06-23 | 2022-12-20 | 临夏州燎原乳业有限公司 | Yak formula milk powder beneficial to cardiovascular health |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305383C (en) * | 2003-11-03 | 2007-03-21 | 东北农业大学 | Active bifidobacteria contained milk powder and its preparation method |
| CN101258875B (en) * | 2008-04-11 | 2010-10-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Yoghourt useful for lowering blood fat and preparation |
| CN102499290B (en) * | 2011-12-27 | 2013-04-10 | 内蒙古伊利实业集团股份有限公司 | Nutrient milk powder with selenium-enriched lentinus edodes and method for producing nutrient milk powder with selenium-enriched lentinus edodes |
| CN102630754A (en) * | 2012-04-18 | 2012-08-15 | 内蒙古蒙牛乳业（集团）股份有限公司 | Compound liquid dairy product with function of assisting in reducing blood fat and preparation method thereof |
-
2012
- 2012-12-03 CN CN201210508501.1A patent/CN102948483B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102948483A (en) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102948483B (en) | Blood fat reducing milk powder and preparation method thereof | |
| CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
| CN102228241A (en) | Health-care food capable of tonifying brain, enhancing intelligence and enhancing memory and preparation method thereof | |
| CN107771946A (en) | A kind of formula milk and its production method for contributing to middle-aged and old cardiovascular and cerebrovascular health | |
| WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN105249175A (en) | Whole nutrition powder capable of conditioning diet and diseases and preparation method thereof | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo leaf flavonoids | |
| CN102422902A (en) | Sea-buckthorn seed and grape seed composite vegetable blend oil and preparation method thereof | |
| KR20100109697A (en) | Functional composition with the effects of improving hyperlipidemia and reducing body weight | |
| CN103829256A (en) | Beverage dissolved with phytosterol and production method thereof | |
| CN100502694C (en) | Ocean functional food with weight-reducing and blood lipoid reducing functions | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN102743547A (en) | Weight-reducing composition with obesity preventing effect and weight-reducing solution | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN112998268A (en) | A method for processing ginsenoside with tumor inhibiting and immunity enhancing effects | |
| JP2003321360A (en) | Fruit oil extracted from plant fruit, method of its extraction, its medicinal composition and use | |
| KR101338498B1 (en) | Method for manufacturing health drink using jujube leaf and health drink manufactured by this | |
| CN102742829A (en) | Dietetic therapy product for regulating blood fat and preparation method thereof | |
| CN104187244A (en) | High-protein composition powder and preparation method thereof | |
| JP2013241467A (en) | Food having human serum hypocholesterolemic activity, and prophylactic or therapeutic agent for human hypercholesterolemia or human arteriosclerosis | |
| CN103478632B (en) | Fruit and vegetable health tablets and method for preparing same | |
| CN102526374B (en) | Hypolipidemic preparation | |
| KR102317197B1 (en) | Health functional food composition using musk rat musk having anti-obesity activity and preparation thereof | |
| JP6770726B1 (en) | Preventive or ameliorating agents for metabolic syndrome | |
| CN107692196A (en) | It is a kind of that there are health products for removing vivotoxin function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130306 Assignee: Durbat Yili Dairy Co.,Ltd. Assignor: Inner Mongolia Yili Industrial Group Co.,Ltd. Contract record no.: X2020980007327 Denomination of invention: A kind of hypolipidemic milk powder and its preparation method Granted publication date: 20140115 License type: Common License Record date: 20201029 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130306 Assignee: Heilongjiang Yili Dairy Co.,Ltd. Assignor: Inner Mongolia Yili Industrial Group Co.,Ltd. Contract record no.: X2020980007546 Denomination of invention: A kind of hypolipidemic milk powder and its preparation method Granted publication date: 20140115 License type: Common License Record date: 20201105 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130306 Assignee: Inner Mongolia Jinze Yili Dairy Co.,Ltd. Assignor: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Contract record no.: X2023990000112 Denomination of invention: A hypolipidemic milk powder and its preparation method Granted publication date: 20140115 License type: Common License Record date: 20230112 |